Cargando…
Acquired Hemophilia A: Current Guidance and Experience from Clinical Practice
In acquired hemophilia A (AHA), autoantibodies to coagulation factor VIII (FVIII) neutralize FVIII activity leading to a potentially severe bleeding diathesis that carries a high rate of morbidity and mortality. This disorder is rare and occurs mainly in adults over 60 years of age or in the postpar...
Autores principales: | Pishko, Allyson M, Doshi, Bhavya S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112043/ https://www.ncbi.nlm.nih.gov/pubmed/35592586 http://dx.doi.org/10.2147/JBM.S284804 |
Ejemplares similares
-
Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century
por: Arruda, Valder R., et al.
Publicado: (2020) -
Emerging therapies for hemophilia: controversies and unanswered questions
por: Arruda, Valder R., et al.
Publicado: (2018) -
Folliculotropic Mycosis Fungoides: Current Guidance and Experience from Clinical Practice
por: Roccuzzo, Gabriele, et al.
Publicado: (2022) -
Acquired Hemophilia
por: Özsoylu, Şinasi
Publicado: (2014) -
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance
por: Schutgens, Roger E.G., et al.
Publicado: (2023)